ReviewMediators of inflammation2017
Advances in Immunotherapy for Melanoma: A Comprehensive Review.
Review in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 142 citations in OpenAlex.
- Canine Adipose-Derived Mesenchymal Stromal Cells Reduce Cell Viability and Migration of Metastatic Canine Oral Melanoma Cell Lines In Vitro.Veterinary sciences · 2024Article
- Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.EClinicalMedicine · 2024Article
- Exosome-based immunotherapy as an innovative therapeutic approach in melanoma.Cell communication and signaling : CCS · 2024Review
- Mesoporous silica coated spicules for photodynamic therapy of metastatic melanoma.Journal of nanobiotechnology · 2024Article
- Predicting immunotherapy response in melanoma using a novel tumor immunological phenotype-related gene index.Frontiers in immunology · 2024Article
- Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects.International journal of molecular sciences · 2023Review
- Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.Cellular and molecular neurobiology · 2023Article
- Macrophage plasticity and function in cancer and pregnancy.Frontiers in immunology · 2023Review
- Article
- Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Frontiers in oncology · 2023Review
- A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis.Frontiers in oncology · 2023Article
- Diagnostic and Prognostic Deep Learning Applications for Histological Assessment of Cutaneous Melanoma.Cancers · 2022Review
- TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.Cytotechnology · 2022Article
- Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.International journal of molecular sciences · 2022Article
- Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib.Scientific reports · 2022Article
- An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2022Article
- B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.Frontiers in immunology · 2022Article
- A Ferroptosis-Related Gene Signature for Predicting Survival and Immunotherapy Effect in Renal Cancer.Computational and mathematical methods in medicine · 2022Article
- Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.Oncoimmunology · 2022Review
- First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?JMIR cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanomas are tumors originating from melanocytes and tend to show early metastasis secondary to the loss of cellular adhesion in the primary tumor, resulting in high mortality rates. Cancer-specific active immunotherapy is an experimental form of treatment that stimulates the immune system to recognize antigens on the surface of cancer cells. Current experimental approaches in immunotherapy include vaccines, biochemotherapy, and the transfer of adoptive T cells and dendritic cells. Several types of vaccines, including peptide, viral, and dendritic cell vaccines, are currently under investigation for the treatment of melanoma. These treatments have the same goal as drugs that are already used to stimulate the proliferation of T lymphocytes in order to destroy tumor cells; however, immunotherapies aim to selectively attack the tumor cells of each patient. In this comprehensive review, we describe recent advancements in the development of immunotherapies for melanoma, with a specific focus on the identification of neoantigens for the prediction of their elicited immune responses. This review is expected to provide important insights into the future of immunotherapy for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.